iNOS/NO signaling regulates apoptosis induced by glycochenodeoxycholate in hepatocytes

被引:30
作者
Wang, Kewei [1 ,2 ]
Brems, John J. [3 ]
Gamelli, Richard L. [3 ]
Holterman, Ai-Xuan [1 ,2 ]
机构
[1] Rush Univ, Med Ctr, Pediat Surg Sect, Dept Pediat, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Pediat Surg Sect, Dept Surg, Chicago, IL 60612 USA
[3] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA
关键词
iNOS; Hepatocyte; Apoptosis; Cholestatic liver disease; NITRIC-OXIDE SYNTHASE; CASPASE ACTIVATION; S-NITROSYLATION; KAPPA-B; CELL; SURVIVIN; LIVER; INJURY; EXPRESSION; NO;
D O I
10.1016/j.cellsig.2011.06.003
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) can ameliorate apoptosis induced by toxic glycochenodeoxycholate (GCDC) in hepatocytes. However, the underlying molecular mechanisms are not yet understood in detail. This study is to clarify the function of iNOS/NO and its mechanisms during the apoptotic process. The apoptosis was brought about by GCDC in rat primary hepatocytes. iNOS/NO signaling was then investigated. iNOS inhibitor 1400 W enhanced the GCDC-induced apoptosis as reflected by caspase-3 activity and TUNEL assay. Exogenous NO regulated the apoptosis subsequent to NO donor S-nitroso-N-acetyl-penicillamine (SNAP) or sodium nitroprusside (SNP). The GCDC-induced apoptosis was decreased with 0.1 mM SNAP or 0.15 mM SNP. while it was increased with 0.8 mM SNAP or 1.2 mM SNP. The endogenous iNOS inhibited apoptosis, but the exogenous NO played a dual role during the GCDC-induced apoptosis. There was a potential iNOS/Akt/survivin axis that inhibited the hepatocyte apoptosis in low doses of NO donors. In contrast, high doses of NO donors activated CHOP through p38MAP-kinase (p38MAPK), upregulated TRAIL receptor DR5, and suppressed survivin. Consequently the high doses of NO donors promoted the apoptosis in hepatocytes. Our data suggest that the iNOS/NO signaling can modulate Akt/survivin and p38MAPK/CHOP pathways to mediate the GCDC-induced the apoptosis in hepatocytes. These signaling pathways may serve as targets for therapeutic intervention in cholestatic liver disease. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1677 / 1685
页数:9
相关论文
共 44 条
[1]
Abrams J., 1996, AM J CARDIOL, V77, pC31
[2]
ALBINA JE, 1993, J IMMUNOL, V150, P5080
[3]
Nitric oxide and inducible nitric oxide synthase expression are downregulated in acute cholestasis in the rat accompanied by liver ischemia [J].
Barón, V ;
Hernández, J ;
Noyola, M ;
Escalante, B ;
Muriel, P .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY, 2000, 127 (03) :243-249
[4]
Inducible nitric oxide synthase: Correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma [J].
Brennan, Peter A. ;
Dennis, Simon ;
Poller, David ;
Quintero, Marisol ;
Puxeddu, Roberto ;
Thomas, Gareth J. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (02) :208-214
[5]
Glycochenodeoxycholate (GCDC) inhibits cytokine induced NOS expression in rat hepatocytes [J].
Bucher, Brian T. ;
Feng, Xuesheng ;
Jeyabalan, Geetha ;
Zhang, Baochun ;
Shao, Lifang ;
Guo, Zhong ;
Geller, David A. .
JOURNAL OF SURGICAL RESEARCH, 2007, 138 (01) :15-21
[6]
Chang WW, 2008, J VIRAL HEPATITIS, V15, P490, DOI [10.1111/j.1365-2893.2008.00968.x, 10.1111/j.1365-2893.2007.00968.x]
[7]
Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells [J].
Chao, JI ;
Kuo, PC ;
Hsu, TS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (19) :20267-20276
[8]
Nitric oxide as a bioregulator of apoptosis [J].
Chung, HT ;
Pae, HO ;
Choi, BM ;
Billiar, TR ;
Kim, YM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (05) :1075-1079
[9]
Protection of early phase hepatic ischemia-reperfusion injury by cholinergic agonists [J].
Crockett, Elahe ;
Galligan, James ;
Uhal, Bruce ;
Harkema, Jack ;
Roth, Robert ;
Pandya, Kinnari .
BMC CLINICAL PATHOLOGY, 2006, 6 :13P
[10]
D'Ambrosio SM, 2001, ENVIRON MOL MUTAGEN, V37, P46, DOI 10.1002/1098-2280(2001)37:1<46::AID-EM1005>3.0.CO